GH Research

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Stock,Market,Graph,Trading,Analysis,Investment,Financial,,Stock,Exchange,Financial

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AKBA

EFXT

GHRS

MAZE

MCHP

TIGR

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Crude Oil and Petroleum Trade in the Crosshairs

Earnings

Equities

Eurozone

Commodities

Intraday Update

HCWB

NSSC

TNXP

Crude Oil Moves Higher; Owens &amp; Minor Shares Plummet

Wall Street_Dow

Dow Falls 150 Points; ISM Manufacturing PMI Rises In January

GH Research PLC

Biotech

Press Releases

General

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

Financing

GH Research Announces Proposed Public Offering

IPOs

GH Research Announces Pricing of $150 Million Public Offering

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

Health Care

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Arvinas

ATAI Life Sciences

Avadel Pharmaceuticals plc - Ordinary Share

Avadel Pharmaceuticals

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Cronos Group

Evolus

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

LENZ Therapeutics

Maze Therapeutics

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine

Nuvation Bio

Oculis Holding

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Pharvaris

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Septerna

SIGA Technologies

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Trevi Therapeutics

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Zevra Therapeutics

Guggenheim

HC Wainwright & Co.

RBC Capital

Stifel

Comments

GH Research

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell